Aurora Cannabis Inc (NYSE:ACB) – Research analysts at Piper Jaffray Companies issued their FY2019 earnings estimates for shares of Aurora Cannabis in a note issued to investors on Monday, August 12th. Piper Jaffray Companies analyst M. Lavery anticipates that the company will earn ($0.26) per share for the year. Piper Jaffray Companies currently has a “Neutral” rating and a $7.00 target price on the stock. Piper Jaffray Companies also issued estimates for Aurora Cannabis’ Q4 2019 earnings at ($0.02) EPS, Q1 2020 earnings at ($0.02) EPS, Q2 2020 earnings at ($0.02) EPS, Q3 2020 earnings at ($0.01) EPS, Q4 2020 earnings at $0.00 EPS, FY2020 earnings at $0.05 EPS, Q1 2021 earnings at $0.01 EPS, Q2 2021 earnings at $0.01 EPS, Q3 2021 earnings at $0.02 EPS, Q4 2021 earnings at $0.02 EPS and FY2021 earnings at $0.05 EPS.
Other equities analysts also recently issued research reports about the stock. ValuEngine downgraded shares of Aurora Cannabis from a “buy” rating to a “hold” rating in a research note on Friday, August 2nd. Stifel Nicolaus began coverage on shares of Aurora Cannabis in a research note on Wednesday, June 5th. They issued a “hold” rating for the company. Zacks Investment Research downgraded shares of Aurora Cannabis from a “buy” rating to a “sell” rating in a research note on Thursday. Compass Point began coverage on shares of Aurora Cannabis in a research note on Monday, July 8th. They set a “neutral” rating for the company. Finally, Desjardins began coverage on shares of Aurora Cannabis in a research note on Thursday, April 25th. They set a “buy” rating and a $9.07 target price for the company. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $8.23.
Aurora Cannabis (NYSE:ACB) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.05). Aurora Cannabis had a negative net margin of 122.65% and a positive return on equity of 1.24%. The company had revenue of $49.00 million during the quarter, compared to analyst estimates of $50.92 million.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Moisand Fitzgerald Tamayo LLC purchased a new position in Aurora Cannabis during the first quarter worth about $25,000. Financial Management Professionals Inc. raised its holdings in Aurora Cannabis by 586.3% during the first quarter. Financial Management Professionals Inc. now owns 3,061 shares of the company’s stock worth $28,000 after purchasing an additional 2,615 shares in the last quarter. Carroll Financial Associates Inc. purchased a new position in Aurora Cannabis during the first quarter worth about $27,000. Burt Wealth Advisors raised its holdings in Aurora Cannabis by 1,033.3% during the first quarter. Burt Wealth Advisors now owns 3,400 shares of the company’s stock worth $31,000 after purchasing an additional 3,100 shares in the last quarter. Finally, Mackey Komara & Dankovich LLC purchased a new position in Aurora Cannabis during the second quarter worth about $27,000. Institutional investors and hedge funds own 9.10% of the company’s stock.
About Aurora Cannabis
Aurora Cannabis Inc produces and distributes medical cannabis products. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution.
Read More: Should I invest in “strong buy” stocks?
Receive News & Ratings for Aurora Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurora Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.